1. Introduction {#sec1-genes-10-00735}
===============

One of the most common sensory impairments is hearing loss (HL), affecting one in 500 to 700 newborns \[[@B1-genes-10-00735]\]. To date, roughly a hundred genes have been reported as associated with inherited non-syndromic HL, and at least half of prelingual HL cases account for genetic factors \[[@B1-genes-10-00735],[@B2-genes-10-00735]\]. Among these reported genes, around 65% are a cause for autosomal recessive sensorineural hearing loss (ARSNHL), and over 70 causative genes have been identified \[[@B2-genes-10-00735]\]. The major causative genes of ARSNHL patients in Japan are *GJB2* (14.8%), *SLC26A4* (4.6%) and *CDH23* (3.4%) \[[@B3-genes-10-00735]\]. Less common causative genes such as *LOXHD1* are rarely detected in SNHL patients, making it difficult to diagnose. The detection of the cause of a patient with HL is relevant, since their etiology could enable us to predict their treatment outcome, and thus provide useful information to better assistant the decision making regarding their course of treatment and/or HL intervention. By introducing massively parallel DNA sequencing (MPS) screening of 68 deafness-causative genes, detection of novel variants of rare causative genes have simplified significantly.

*LOXHD1* is a known cause of DFNB77, a progressive form of ARSNHL. It is mapped on chromosome 18q12--21, and it encodes the protein Lipoxygenase Homology Domains 1, which consists entirely of 15 PLAT (polycystin-1, lipoxygenease, alpha-toxin) domains \[[@B4-genes-10-00735]\]. Grillet et al. previously reported in murine studies that Loxhd1 proteins are localized in hair cells along the plasma membrane of stereocilia, which helps maintain normal hair cell function \[[@B5-genes-10-00735]\]. They reported HL in *samba* mice due to the rapid degeneration of cochlear hair cells shortly after birth.

Studies have shown that the variations of the *LOXHD1* gene show progression of HL, leading to profound to severe non-syndromic HL. However, not many studies have reported its accompanying phenotypes, including the severity, progression and vestibular function, thus the correlation of genotype and phenotype is unclear. In this study, we detected a large group of HL patients with *LOXHD1* variations. Here, we report the novel variations detected by MPS and assess the phenotypes of patients with *LOXHD1* variation.

2. Materials and Methods {#sec2-genes-10-00735}
========================

2.1. Subjects {#sec2dot1-genes-10-00735}
-------------

For this study, a total of 8074 Japanese HL patients (autosomal dominant sensorineural hearing loss, 1336; ARSNHL, 5564; and inheritance unknown, 1174) were recruited from 67 otolaryngology departments nationwide described in our previous reports \[[@B6-genes-10-00735]\]. Among these subjects, we selected patients with *LOXHD1* variants by using MPS on 68 target genes ([Table S1](#app1-genes-10-00735){ref-type="app"}). To participate in this study, a written informed consent was obtained from all patients (or from their next of kin, caretaker or guardian in case of minors or children), which was approved by the Shinshu University Ethical Committee and the ethical committee within each participating institution. Clinical information and peripheral blood samples were obtained from each subject and from all their consenting relatives.

This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Shinshu University School of Medicine No. 387---4 September 2012, and No. 576---2 May 2017.

2.2. Variant Analysis {#sec2dot2-genes-10-00735}
---------------------

Amplicon libraries of the target exons were prepared with an Ion AmpliSeq Custom Panel (ThermoFisher Scientific, Waltham, MA, USA) designed using Ion AmpliSeq Designer for 68 genes reported to cause nonsyndromic hearing loss with the Ion AmpliSeq Library Kit 2.0 (ThermoFisher Scientific) and Ion Xpress Barcode Adapter 1-96 Kit (ThermoFisher Scientific) according to the manufacturer's instructions \[[@B7-genes-10-00735],[@B8-genes-10-00735]\]. The detailed protocol has been described elsewhere \[[@B8-genes-10-00735]\]. After the amplicon libraries were prepared, equal amounts of the libraries for six patients were pooled for one Ion PGM sequence reaction and those for 45 patients were pooled for one Ion Proton sequencing. The emulsion PCR was performed with the Ion OneTouch System and Ion OneTouch 200 Template Kit v2 (ThermoFisher Scientific) or Ion PI Hi-Q OT2 200 Kit according to the manufacturer′s instructions. Sequencing was performed with an Ion torrent PGM system using the Ion PGM 200 Sequencing Kit and Ion 318 Chip (Thermo- Fisher Scientific), or Ion Proton system using the Ion PI Hi-Q Sequencing 200 Kit and Ion PI Chip (ThermoFisher Scientific) according to the manufacturer′s instructions.

The sequence data were mapped against the human genome sequence (build GRCh37/ hg19) with a Torrent Mapping Alignment Program. After sequence mapping, the DNA variant regions were piled up with Torrent Variant Caller plug-in software. After variant detection, their effects were analyzed using ANNOVAR software \[[@B9-genes-10-00735]\]. The missense, nonsense, insertion/deletion and splicing variants were selected from among the identified variants. Variants were further selected as less than 1% of the 1000-genome database, the 6500 exome variants, the Human Genetic Variation Database (dataset for 1208 Japanese exome variants) and the 333 in-house Japanese normal hearing controls. Direct sanger sequencing was utilized to confirm the selected variants. Copy number analysis based on the read depth data obtained from NGS analysis was also performed for all 68 genes in accordance to our previous paper \[[@B8-genes-10-00735]\].

The allele frequency of a variant was evaluated by the Exome Aggregation Consortium (ExAC03) and the Genome Aggregation Database (gnomAD). The pathogenicity of a variant was evaluated by ACMG (American College of Medical Genetics) standards and guidelines \[[@B10-genes-10-00735]\]. For missense variants in particular, functional prediction software, including Sorting intolerant from Tolerant (SIFT), Polymorphism Phenotyping (PolyPhen2), Likelihood Ratio Test (LRT), Mutation Taster, Mutation Assessor and Combined Annotation Dependent Depletion (CADD) were used in the ANNOVAR software.

2.3. Clinical Evaluations {#sec2dot3-genes-10-00735}
-------------------------

We collected the onset age and progressiveness of HL, pedigree, complaints of tinnitus and vertigo. Further vestibular examinations, e.g., measurement of cervical and ocular vestibular evoked myogenic potential (cVEMP and oVEMP) and caloric testing, were obtained from some patients. Evaluation of HL by pure-tone audiometry was performed on patients over 5 years old, and the auditory steady state response (ASSR), conditioned orientation response audiometry (COR; one of the behavioral audiometries) or play audiometry was performed on patients under 4 years old. The pure tone average (PTA) was calculated from the audiometric thresholds at four frequencies (0.5, 1, 2 and 4 kHz). We classified their HL into 4 categories: mild (PTA 20--40 dB), moderate (41--70 dB), severe (71--90 dB) and profound (\>91 dB). The audiometric configurations were categorized to flat, low-frequency HL, mid-frequency HL, sloping high-frequency HL (gradually falling 10 dB for high frequency) and precipitous high-frequency HL (higher frequency thresholds worsen by at least 20 dB per octave) as reported previously \[[@B11-genes-10-00735]\].

Intervention outcome for HL, including the use of cochlear implants, was analyzed based on medical charts.

2.4. Haplotype Analysis {#sec2dot4-genes-10-00735}
-----------------------

Haplotype pattern within the 2 Mbp region surrounding position hg19:chr18:44114297, for the frequent Japanese variation *LOXHD1*:NM_144612:c.4212+1G\>A identified in this study, was analyzed using a set of 32 single nucleotide polymorphisms (SNPs) (16 sites upstream and 16 sites downstream). For this analysis, we selected 6 patients with this homozygous variation. Haplotype analysis was performed by the direct sanger sequencing.

3. Results {#sec3-genes-10-00735}
==========

3.1. Detected Variations {#sec3dot1-genes-10-00735}
------------------------

We identified 21 possibly disease-causing *LOXHD1* variants, 13 of which were novel variants ([Table 1](#genes-10-00735-t001){ref-type="table"}). All individuals with novel variants belonged to independent pedigrees except for 1 sibling ([Figure 1](#genes-10-00735-f001){ref-type="fig"}). The novel variants consisted of 7 missense variants, 1 nonsense variant, 4 splicing variants and 1 frameshift deletion variant. The allele frequency of all variants was less than 0.01% using the aforementioned database. Based on the ACMG guidelines, the novel variants were categorized into 2 pathogenic, 4 likely pathogenic and 7 uncertain significance. The segregation analysis is not complete on some pedigrees since we could not obtain peripheral blood samples from all the family members. This could indicate that the *LOXHD1* variants could possibly not be the cause of the patient′s HL, yet, our filtering process detected no other biallelic candidate variants of other recessive genes from the MPS results. Specifically, families \#21 and \#22 looks to be possibly of dominant or X-linked heredity, and only the *LOXHD1* mutations remained after filtering, thus we included these two cases. To further confirm that two *LOXHD1* variants are in *trans* allele and be the causative gene of their HL, further analysis by the long-read sequencing could be considered. Notably, among the eight previously reported *LOXHD1* variants that were also identified in this study, the c.1828G \> A and c.3281A \> G variants had relatively high carrier frequencies in the Japanese control population database (Human Genetic Variation Database (HGVD) and 3.5KJPN-Integrative Japanese Genome Variation Database) \[[@B12-genes-10-00735],[@B13-genes-10-00735]\]. The minor allele frequency (MAF) of c.1828G \> A in the Japanese control was 0.7% (70/9510 allele), whereas c.3281.A \> G was 0.2% (2/9454 allele). These carrier frequencies were relatively higher compared to those of other population datasets (ExAc, gnomAD). Thus, the pathogenicity of these two variants are controversial.

3.2. Clinical Features of Patients with LOXHD1 Variants {#sec3dot2-genes-10-00735}
-------------------------------------------------------

In this study, 28 affected individuals from 25 families were identified, which include 3 previously reported individuals \[[@B15-genes-10-00735],[@B21-genes-10-00735]\]. Their clinical findings are summarized on [Table 2](#genes-10-00735-t002){ref-type="table"}.

The onset age of their HL varied from 0 to 36 years old (mean age: 6.1 years), among which 14 patients had congenital HL. Only four individuals noticed their HL post childhood. A total of 6 out of 21 patients (28.5%) complained of tinnitus, and none of vertigo. A total of 15 out of 28 individuals (53.6%) were aware of progression of HL at the time of their genetic testing. To further assess the progression of HL, we evaluated the deterioration of hearing by obtaining serial audiograms from 14 individuals ([Figure 2](#genes-10-00735-f002){ref-type="fig"}). The deterioration rate varied from 0.1 dB/year to 9.3 dB/year in PTA (mean rate: 3.5 dB/year). This further follow up revealed progression of HL in four individuals unaware of deterioration of HL at the time of their genetic testing.

We acquired audiograms from 27 individuals ([Figure 1](#genes-10-00735-f001){ref-type="fig"}). All individuals presented bilateral HL, and 25 presented symmetrical HL, except for two individuals (family no. 13 and 21). The audiometric configurations were classifiable into 14 flat types, 8 sloping high-frequency HL and 6 precipitous high frequency HL audiograms. Their severity of HL at the point of genetic examination varied from mild to profound, including 3 mild HL (11%), 7 moderate HL (26%), 6 severe HL (22%) and 11 profound HL (41%).

3.3. Recurrent Variant {#sec3dot3-genes-10-00735}
----------------------

A recurrent variation, c.4212 + 1G \> A, was identified in 9 individuals with this homozygous variant and in 9 with this compound heterozygous variant. Between these variants, there was no specific difference in the phenotypes. When compared age wise, older individuals showed a significant deterioration of HL ([Figure 3](#genes-10-00735-f003){ref-type="fig"}). Specifically, patients in their youth showed varying degrees of HL from mild to profound HL, whereas patients over adolescence all showed severe to profound HL.

This variant has only been reported in the Japanese HL patients ([Table 3](#genes-10-00735-t003){ref-type="table"}). To evaluate whether this variant is a common ancestor phenomenon or mutational hot spot, we performed a haplotype analysis on six homozygous variant patients, which presented differing haplotypes ([Table 4](#genes-10-00735-t004){ref-type="table"}).

Though less in number, c.3281A \> G was another recurrently identified variation. Four individuals with this compound heterozygous variation were identified in this study. Two individuals (family no. 16 and 19) with missense compound heterozygous variations showed late onset of over 30 years old ([Table 2](#genes-10-00735-t002){ref-type="table"}). The other two individuals (family no. 11 and 23) had compound heterozygous variations with the other recurrent c.4212 + 1G \> A, and they both presented early onset severe HL. All individuals with this variation exhibited severe to profound HL at the time of their genetic testing ([Figure 1](#genes-10-00735-f001){ref-type="fig"}, family no. 11, 16, 19 and 23). This variation has previously been reported among the Chinese population, yet no clinical characteristics were presented in the paper \[[@B16-genes-10-00735]\].

3.4. Intervention {#sec3dot4-genes-10-00735}
-----------------

Of the 28 individuals, eight individuals were reported to have received cochlear implantation (CI). We followed up on four of these individuals (family no. 1, 6, 13 and 22) after CI. We were able to obtain complete results of the Japanese monosyllable, word and sentence perception tests pre-CI from two of these four patients. These two recieved CI in their adulthood, and showed a precipitous type of audiogram configuration. All CI patients showed a favorable outcome and showed over 90% correct six months post-operation ([Figure 4](#genes-10-00735-f004){ref-type="fig"}).

4. Discussion {#sec4-genes-10-00735}
=============

In this study, we identified 28 individuals with *LOXHD1* variants including 13 novel variants by MPS screening. A total of 44 *LOXHD1* variants have been reported to date from various countries, and this study is the largest analysis of *LOXHD1*-related HL yet ([Table 3](#genes-10-00735-t003){ref-type="table"}) \[[@B5-genes-10-00735],[@B14-genes-10-00735],[@B15-genes-10-00735],[@B16-genes-10-00735],[@B17-genes-10-00735],[@B18-genes-10-00735],[@B19-genes-10-00735],[@B20-genes-10-00735],[@B21-genes-10-00735],[@B22-genes-10-00735],[@B23-genes-10-00735],[@B24-genes-10-00735],[@B25-genes-10-00735],[@B26-genes-10-00735],[@B27-genes-10-00735],[@B28-genes-10-00735],[@B29-genes-10-00735],[@B30-genes-10-00735],[@B31-genes-10-00735],[@B32-genes-10-00735],[@B33-genes-10-00735],[@B34-genes-10-00735]\]. Among the identified variants, 11 were non-truncating variations (52.4%) and 10 were truncating variations (47.6%). This ratio is consistent with the previously reported 26 non-truncating variations and 18 truncating variations ([Table 3](#genes-10-00735-t003){ref-type="table"}).

The prevalence of *LOXHD1*-gene associated HL was 0.365% (28/8074) of SNHL probands and 0.50% (28/5564) of ARSNHL probands in this Japanese population. The estimated frequency of Japanese HL patients with *LOXHD1* c.4212 + 1G \> A homozygous variation, calculated from the carrier frequencies observed in HGVD and 3.5KJPN \[[@B12-genes-10-00735],[@B13-genes-10-00735]\], was 0.14%. Our studies showed the frequency of this homozygous variation to be 0.1% (8/8,074), which support the accuracy of the prevalence estimated from this study \[[@B34-genes-10-00735],[@B35-genes-10-00735]\]. The prevalence of this gene is notably lower than that of other more common ARSNHL causing genes, such as *GJB2*, *SLC26A4* and *CDH23*. Few previous reports have discussed the prevalence of the *LOXHD1* gene amongst SNHL patients. In relatively large cohorts that evaluated more than 100 patients, the prevalence of this gene was estimated to 0.71% in American SNHL patients (8/1119), 1.5% in the Netherlands (3/200) and 0.97% in Italy (1/103) \[[@B19-genes-10-00735],[@B22-genes-10-00735],[@B28-genes-10-00735]\]. This result is similar with our study in the American patients, but noticeably higher in the other two countries. Yet, there are limitations to discuss these differences because of the variance of their cohort sizes.

We analyzed the phenotypes of *LOXHD1* gene variation from various points. In this study, 85.7% (24/28) had an early onset HL. Among the four individuals with late onset HL, two had the same variation, c.3281A \> G, and they were the only two cases with two missense compound heterozygous variations. The individuals who did not have this variation (family no. 21 and 22) both presented precipitous high-frequency HL at the time of their genetic testing. This suggests that their deterioration in hearing might have been undetected due to the lack of neonatal hearing screening or lack of regular audiometric examination. Previous reports mainly support that HL due to *LOXHD1* is congenital or of early onset, but some of the patients also showed late onset HL \[[@B20-genes-10-00735],[@B27-genes-10-00735]\].

We identified that 64.3% (18/28) patients presented progression of their HL, and serial audiograms of several individuals revealed the deterioration rate of HL varying from slow to rapid declining HL. Interestingly, we identified that individuals with c.4212 + 1G \> A, a recurrent variation only reported in Japanese HL patients ([Table 4](#genes-10-00735-t004){ref-type="table"}), show relatively rapid progression in HL and most of their HL deteriorated to severe to profound HL in their first decade ([Figure 3](#genes-10-00735-f003){ref-type="fig"}). There have been controversial arguments to whether *LOXHD1* variations present progression in HL \[[@B5-genes-10-00735],[@B14-genes-10-00735],[@B15-genes-10-00735],[@B16-genes-10-00735],[@B17-genes-10-00735],[@B18-genes-10-00735],[@B19-genes-10-00735],[@B20-genes-10-00735],[@B21-genes-10-00735],[@B22-genes-10-00735],[@B23-genes-10-00735],[@B24-genes-10-00735],[@B25-genes-10-00735],[@B26-genes-10-00735],[@B27-genes-10-00735],[@B28-genes-10-00735],[@B29-genes-10-00735],[@B30-genes-10-00735],[@B31-genes-10-00735],[@B32-genes-10-00735],[@B33-genes-10-00735],[@B34-genes-10-00735]\]. This study has revealed that most cases showed progressive HL or congenital deaf and some showed relatively stable HL. The HL progression of *LOXHD1*-associated HL may individually differ.

We also compared the severity of HL by type of mutation (non-truncating vs. truncating), by classifying the variations into PLAT domains, and by age. The results were inconclusive, and even in the patients with the same variations showed various phenotypes, especially, regardless of the same pedigree (family no. 8). We conclude that the varying phenotypes may be due to other environmental or genetic factors.

No individuals exhibited accompanying symptoms to *LOXHD1* related HL in this study. Riazzudin et al. have reported this gene mutation to be a cause of late onset Fuchs corneal dystrophy \[[@B35-genes-10-00735]\], yet there were no cases that distributed optic symptoms in this study. Grillet et al. previously reported, though not as prominent as in the cochlear stereocilia, *Loxhd1* is expressed in the stereocilia of vestibular hair cells, though no vestibular symptoms were observed in the murine study \[[@B5-genes-10-00735]\]. They observed *Loxhd1* expression to become prominent when cochlear stereocilia shed the kinocilium in its development, and suggested that the Loxhd1 protein help stabilize the stereociliary bundle in the absence of the kinocilium. They hypothesized that the discrepancy between *Loxhd1* expression in vestibular stereocilia and lack of vestibular function is because the vestibular stereocilia do not shed its kinocilium. In this study, no patients complained of vertigo, and also in further vestibular examinations, cVEMP, oVEMP and caloric testing of six individuals (family no. 1, 6, 13, 22, 23) showed no vestibular dysfunction ([Table 2](#genes-10-00735-t002){ref-type="table"}). Wesdorp et al. have also published results similar to this study that among the 14 individuals with *LOXHD1* variants that they identified, none revealed abnormalities under ophthalmological and vestibular evaluation \[[@B14-genes-10-00735]\]. These clinical findings might support Grillet's hypothesis.

A recurrent variant c.4212 + 1G \> A was detected in 64.3% (18/28) individuals in this study. This variant has only been reported among the Japanese HL patients. This insinuates that this variation is a mutation hot spot, or a common ancestor phenomenon. Our haplotype analysis revealed differing haplotypes, suggesting that it is a mutation hot spot, or that multiple ancestors of Japanese population had this mutation. On the gnomAD database, this variation has been detected in Africans, East Asians and non-Finnish Europeans, which could also support this hypothesis. No other variations have previously been reported to recur by the common ancestor phenomenon.

Eppsteiner et al. hypothesized that HL patients due to gene variations that are expressed in the membranous labyrinth produce better results with CI than patients that have HL due to gene variations expressed in the spiral ganglion \[[@B20-genes-10-00735]\]. As they also reported, since *LOXHD1* are expressed in cochlear stereocilias, it can be predicted that patients with this gene variation are good candidates for CI. This study showed that all patients with the *LOXHD1* variation who received CI showed favorable outcomes; all four cases for which we were able to obtain the results of the Japanese monosyllable word and sentence perception tests, showed over 90% correctness.

In conclusion, by analyzing the largest number of patients with *LOXHD1* related HL yet to be reported, we determined several characteristics of *LOXHD1* variations, and recurrent variants. In most cases, early onset is to be expected in patients with this gene variant. Rapid progression is commonly observed in patients with the c.4212+1G\>A variation, yet other variants show a different rate of deterioration in HL. In this study, no symptoms accompanied HL with *LOXHD1* variations. The varying phenotypes can be the result of environmental and/or other genetic factors. All patients who received CI showed favorable outcomes regardless of their pre-operative clinical features, and it can be predicted that patients with *LOXHD1* variations are good candidates for CI.
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The following are available online at <https://www.mdpi.com/2073-4425/10/10/735/s1>, Table S1: 68 Deafness-causative genes.
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Pedigree and audiograms for each family with *LOXHD1* variants. Arrows show the probands in each family (family numbers 1--25). Genetic findings for each individual tested are noted in the pedigree. The age at the time of their genetic and audiometric testing is noted below the audiogram. ＊ These families include the variations mentioned in the footnote of [Table 1](#genes-10-00735-t001){ref-type="table"}.
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![Serial audiograms of eight individuals with *LOXHD1* variations. Darker colors indicate the hearing thresholds in younger ages, and lighter colors indicate those in older ages.](genes-10-00735-g002){#genes-10-00735-f002}

![Overlapping audiograms of individuals with c.4212 + 1G \> A variation. Pure-tone audiograms or conditioned orientation response audiograms were utilized. Darker colors indicate the hearing thresholds in younger ages, and lighter colors indicate those in older ages. Their ages ranged from 0 to 69 years old.](genes-10-00735-g003){#genes-10-00735-f003}

![Mean scores of the Japanese monosyllable, word and sentence tests pre-cochlear implantation (CI) and six months post-CI. The scores pre-CI are with hearing aids. *n* = 2 pre-CI (*n* = 3 in word perception tests pre-CI) and *n* = 4 post-CI.](genes-10-00735-g004){#genes-10-00735-f004}
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###### 

All possibly pathogenic *LOXHD1* gene variants identified in this study (NM_144612).

                                                                                           Allele Frequency Information   ANNOVAR dbNSFP ver 3.5                                                                       
  ------------------ ------------------ -------------------------------------------------- ------------------------------ ------------------------ ----------- ----------- ----------- ----------- ----------- ------- ---------------------------------------------------------------------------------------------
  c.246 − 1G \> A                       Pathogenic (PVS1,PM2,PM3,PP1,PP3)                  \-                             \-                       \-          \-          \-          D (0.81)    \-          26.7    This Study
  c.1270 + 4A \> C                      Likely Pathogenic (PVS1, PM2)                      \-                             \-                       \-          \-          \-          \-          \-          \-      This Study
  c.1828G \> A       p.E610K            Uncertain Significance (PM3, PP3, BS1)             4.602e−05                      5.3e−05                  D (0.614)   D (0.85)    D (0.629)   D (0.548)   M (0.743)   25      \[[@B14-genes-10-00735]\] ＊
  c.2726C \> T       p.T909M            Uncertain Significance (PM2, BP4)                  \-                             6.785e−06                D (0.443)   B (0.214)   N (0.383)   D (0.81)    L (0.263)   10.25   This Study
  c.3076G \> T       p.V1026F           Uncertain Significance (PM2, PM3, PP3, PP5)        \-                             \-                       D (0.721)   D (0.754)   D (0.537)   D (0.81)    H (0.932)   15.91   \[[@B15-genes-10-00735]\]
  c.3281A \> G       p.D1094G           Uncertain significance (PP3, PM7, PP3, PP5, BS1)   0                              5.883e−05                D (0.555)   D (0.916)   D (0.843)   D (0.81)    H (0.973)   15.22   \[[@B16-genes-10-00735]\] ＊
  c.3578C \> T       p.A1193V           Uncertain Significance (PM2, PP3)                  \-                             \-                       D (0.682)   D (0.818)   D (0.523)   D (0.81)    H (0.970)   33      This Study
  c.3857G \> T       p.G1286V           Likely Pathogenic (PM2, PM3, PP1, PP3)             \-                             \-                       D (0.784)   D (0.971)   D (0.743)   D (0.81)    H (0.967)   26.1    This Study
  c.4212 + 1G \> A                      Pathogenic (PVS1, PM2, PM7, PP3, PP5)              \-                             2.65e−05                 \-          \-          \-          D (0.81)    \-          24.2    \[[@B17-genes-10-00735]\]
  c.4213 − 1G \> A                      Pathogenic (PVS1, PM2, PM3)                        \-                             6.6e−06                  \-          \-          \-          D (0.81)    \-          26      This Study
  c.4375 + 1G \> T                      Likely Pathogenic (PVS1, PM2, PM3, PP5)            \-                             \-                       \-          \-          \-          D (0.81)    \-          26.6    \[[@B16-genes-10-00735]\]
  c.4480C \> T       p.E1494X           Pathogenic (PVS1, PM2, PM3, PP1, PP3, PP5)         0.0006                         0.0006                   \-          \-          D (0.843)   A (0.81)    \-          38      \[[@B18-genes-10-00735],[@B19-genes-10-00735],[@B20-genes-10-00735],[@B21-genes-10-00735]\]
  c.4734C \> G       p.Y1578X           Pathogenic (PVS1, PM2, PM3)                        \-                             \-                       \-          \-          D (0.559)   A (0.81)    \-          35      This Study
  c.5086 − 3C \> A                      Pathogenic (PVS1, PM2, PP3)                        \-                             6.623e−26                \-          \-          \-          \-          \-                  This Study
  c.5608C \> T       p.R1870W           Uncertain Significance (PM2, PP3)                  4.499e−05                      3.939e−05                D (0.784)   D (0.916)   \-          D (0.48)    M (0.924)   34      This Study
  c.5734G \> A       p.D1912N           Uncertain Significance (PM2, PM3, PP3,)            \-                             \-                       D (0.912)   D (0.916)   \-          D (0.588)   M (0.632)   28.7    This Study
  c.5869G \> T       p.E1957X           Pathogenic (PVS1, PM2, PM3, PP1, PP5)              \-                             \-                       \-          \-          \-          A (0.81)                54      \[[@B21-genes-10-00735]\]
  c.5885C \> T       p.1962M            Uncertain Significance (PM2, PP1, PP3, PP5)        4.44e−05                       6.544e−06                D (0.784)   D (0.916)   \-          D (0.52)    L (0.44)    34      \[[@B22-genes-10-00735]\]
  c.5933G \> A       p.G1978D           Likely Pathogenic (PM2, PM3, PP1, PP3)             4.531e−05                      6.565e−06                D (0.614)   D (0.679)   \-          D (0.588)   L (0.52)    34      This Study
  c.6037G \> A       p.G2013R           Uncertain Significance (PM2, PM3, PP3)             \-                             \-                       D (0.682)   D (0.971)   \-          D (0.81)    L (0.52)    33      This Study
  c.6168delC         p.C2057Vfs \* 42   Pathogenic (PVS1, PM2, PM3)                        \-                             \-                       \-          \-          \-          \-          \-          \-      This Study

AA: amino acid; PVS: evidence of pathogenicity---Very strong; PM: evidence of pathogenicity---moderate; PP: evidence of pathogenicity---Supporting; BP: evidence of benign---Supporting; BS: evidence of benign---Strong. \* This asterisk indicates the numbers of frameshifts. ＊ The MAF in the Japanese population were relatively higher than that of other populations. The pathogenicity of these variants is controversial.

genes-10-00735-t002_Table 2

###### 

Clinical findings of individuals with *LOXHD1* variants identified in this study (NM_144612).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family No.   Base Change              Amino Acid Change        Onset   Sex   Tinnitus   Verigo   Vestibular Examination (R/L)   Progression   Severity   Configuration
  ------------ ------------------------ ------------------------ ------- ----- ---------- -------- ------------------------------ ------------- ---------- ---------------
  1            c.\[4212 + 1G \> A\];\   p.\[?\];\                0       m     \-         \-       Normal/Normal                  \+            Mild       Flat
               \[3857G \> T\]           \[G1286V\]                                                                                                         

  2            c.\[4212 + 1G \> A\];\   p.\[?\];\                0       m     \-         \-       NA                             \-            Moderate   Flat
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  3            c.\[4212 + 1G \> A\];\   p.\[?\];\                0       f     \-         \-       NA                             \+            Moderate   Precipitous
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  4            c.\[4212 + 1G \> A\];\   p.\[?\];\                0       f     \-         \-       NA                             \-            Moderate   Flat
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  5            c.\[4212 + 1G \> A\];\   p.\[?\];\                0       f     \-         \-       NA                             \-            Severe     Flat
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  6            c.\[5885C \> T\];\       p.\[1962M\];\            0       f     NA         NA       Normal/Normal                  \+            Profound   Flat
               \[246 − 1G \> A\]        \[?\]                                                                                                              

  7\           c.\[4212 + 1G \> A\];\   p.\[?\];\                0       m     NA         \-       NA                             \-            Moderate   Flat
  III-1        \[4212 + 1G \> A\]       \[?\]                                                                                                              

  III-2        c.\[4212 + 1G \> A\];\   p.\[?\];\                0       f     NA         \-       NA                             \-            Moderate   Flat
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  8\           c.\[5869G \> T\];\       p.\[E1957X\];\           0       f     \-         \-       NA                             \+            Severe     Flat
  III-1        \[4480C \> T\]           \[E1494X\]                                                                                                         

  III-2        c.\[5869G \> T\];\       p.\[E1957X\];\           7       m     \-         \-       NA                             \+            Moderate   Flat
               \[4480C \> T\]           \[E1494X\]                                                                                                         

  9            c.\[4213 − 1G \> A\];\   p.\[?\];\                5       m     \-         \-       NA                             \-            Mild       Sloping
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  10           c.\[4375 + 1G \> T\];\   p.\[?\];\                7       f     \-         \-       NA                             \-            Profound   Sloping
               \[3076G \> T\]           \[V1026F\]                                                                                                         

  11           c.\[4212 + 1G \> A\];\   p.\[?\]:\                0       f     \-         \-       NA                             \+            Severe     Sloping
               \[3281A \> G\]           \[D1094G\]                                                                                                         

  12\          c.\[4212 + 1G \> A\];\   p.\[?\];\                2       f     \-         \-       NA                             \+            Profound   Flat
  III-1        \[246-1G\>A\]            \[?\]                                                                                                              

  III-2        c.\[4212 + 1G\>A\];\     p.\[?\];\                0       m     \-         \-       NA                             \+            Profound   Flat
               \[ 246 − 1G \> A\]       \[?\]                                                                                                              

  13           c.\[6168delC\];\         p.\[C2057Vfs \* 42\];\   3       m     \+         \-       Normal/Normal                  \+            Severe     Precipitous
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  14           c.\[4734C \> G\];\       p.\[Y1578X\];\           0       m     \-         \-       NA                             \+            Profound   Sloping
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  15           c.\[4212 + 1G \> A\];\   p.\[?\];\                4       f     NA         NA       NA                             \-            NA         NA
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  16           c.\[5734G \> A\];\       p.\[D1912N\];\           30      f     \+         \-       NA                             \+            Severe     Sloping
               \[3281A \> G\]           \[D1094G\]                                                                                                         

  17           c.\[3578C \> T\];\       p.\[A1193V\];\           0       f     \+         \-       NA                             \-            Moderate   Precipitous
               \[3578C \> T\]           \[A1193V\]                                                                                                         

  18           c.\[6037G \> A\];\       p.\[G2013R\];\           5       f     \+         \-       Normal/Normal                  \+            Profound   Sloping
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  19           c.\[5933G \> A\];\       p.\[G1978D\];\           32      f     \+         \-       NA                             \+            Profound   Precipitous
               \[3281A \> G\]           \[D1094G\]                                                                                                         

  20           c.\[4212 + 1G \> A\];\   p.\[?\];\                0       f     \+         \-       NA                             \-            Profound   Flat
               \[4212 + 1G \> A\]       \[?\]                                                                                                              

  21           c.\[5608C \> T\];\       p.\[R1870W\];\           36      m     NA         NA       NA                             \+            Mild       Precipitous
               \[1270 + 4A \> C\]       \[?\]                                                                                                              

  22           c.\[5086 − 3C \> A\];\   p.\[?\];\                30      f     \+         \-       Normal/Normal                  \+            Profound   Precipitous
               \[2726C \> T\]           \[T909M\]                                                                                                          

  23           c.\[4212 + 1G \> A\];\   p.\[?\]:\                4       f     NA         NA       Normal/Normal                  \+            Severe     Sloping
               \[3281A \> G\]           \[D1094G\]                                                                                                         

  24           c.\[1828G \> A\];\       p.\[E610K\];\            2       f     NA         NA       NA                             \+            Profound   Flat
               \[1828G \> A\]           \[E610K\]                                                                                                          

  25           c.\[4212 + 1G \> A\];\   p.\[?\];\                5       m     \-         \-       NA                             \-            Profound   Flat
               \[4212 + 1G \> A\]       \[?\]                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available, -: No, +: Yes. \* This asterisk indicates the numbers of frameshifts.

genes-10-00735-t003_Table 3

###### 

All previously reported *LOXHD1* gene variations and their clinical features (NM_144612).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nucleotide Change                Amino Acid Change        HL Onset                   Severity of HL       Progression           Population       Reference
  -------------------------------- ------------------------ -------------------------- -------------------- --------------------- ---------------- -------------------------------------------------
  c.\[71delT\];\                   p.\[L24Rfs \* 74\];\     Congenital or Prelingual   Severe or Profound   NA                    Turkish          \[[@B23-genes-10-00735]\]
  \[71delT\]                       \[L24Rfs \* 74\]                                                                                                

  c.\[442A \> T\];\                p.\[K148X\];\            NA                         NA                   NA                    American         \[[@B24-genes-10-00735]\]
  \[4217C \> T\]                   \[A1406V\]                                                                                                      

  c.\[486_487delCTinsGG\];\        p.\[?\];\                NA                         NA                   NA                    Saudi Arabian    \[[@B25-genes-10-00735]\]
  \[486_487delCTinsGG\]            \[?\]                                                                                                           

  c.\[894T \> G\];\                p.\[Y298X\];\            Congenital                 Mild-moderate        NA                    American         \[[@B19-genes-10-00735]\]
  \[6353G \> A\]                   \[G2118E\]                                                                                                      

  c.\[1588C \> T\];\               p.\[E530X\];\            Childhood                  Severe--profound     Progressive           Qatar            \[[@B26-genes-10-00735]\]
  \[1588C \> T\]                   \[E530X\]                                                                                                       

  c.\[1603C \> T\];\               p.\[R535X\];\            Childhood                  Mild--moderate       NA                    American         \[[@B19-genes-10-00735]\]
  \[1938G \> A\]                   \[K646K\]                                                                                                       

  c.\[1618dupA\];\                 p.\[T540Afs \* 24\];\    Congenital                 Severe               Stable--Progressive   Dutch            \[[@B14-genes-10-00735],[@B22-genes-10-00735]\]
  \[1730T \> G\]                   \[L635P\]                                                                                                       

  c.\[1751C \> T\];\               p.\[T584\];\             35--40 y.o.                Severe               Progressive           Chinese          \[[@B27-genes-10-00735]\]
  \[5815G \> A\]                   \[D1939N\]                                                                                                      

  c.\[1730T \> G\];\               p.\[L577R\];\            Congenital                 Severe--profound     NA                    American         \[[@B19-genes-10-00735]\]
  \[5869G \> A\];\                 \[E1957K\];\                                                                                                    
  \[5944C \> T\] ＊                \[R1982X\]                                                                                                      

  c.\[1828G \> T\];\               p.\[E610X\];\            2--4 y.o.                  Mild                 Stable                Dutch            \[[@B14-genes-10-00735]\]
  \[2641G \> A\]                   \[G881R\]                                                                                                       

  c.\[1843C \> T\];\               p.\[R615W\];\            NA                         NA                   NA                    Chinese          \[[@B16-genes-10-00735]\]
  \[3281A \> G\]                   \[D1094G\]                                                                                                      

  c.\[1904T \> C\];\               p.\[L635P\];\            2--3 y.o.                  Mild                 Stable--Progressive   Dutch            \[[@B14-genes-10-00735]\]
  \[4678T \> C\]                   \[C1560R\]                                                                                                      

  c.\[1938G \> A\];\               p.\[K646K\];\            Childhood                  Mild--moderate       NA                    American         \[[@B19-genes-10-00735]\]
  \[4936C \> T\]                   \[C1560R\]                                                                                                      

  c.\[2008C \> T\];\               p.\[R670X\];\            Childhood                  Moderate--profound   Progressive           Iranian          \[[@B5-genes-10-00735]\]
  \[2008C \> T\]                   \[R670X\]                                                                                                       

  c.\[2696G \> C\];\               p.\[R899P\];\            NA                         NA                   NA                    American         \[[@B19-genes-10-00735]\]
  \[3596T \> C\]                   \[L1199P\]                                                                                                      

  c.\[2696G \> C\];\               p.\[R899P\];\            5 y.o.                     Moderate             Stable                Dutch            \[[@B14-genes-10-00735]\]
  \[3834G \> C\]                   \[W1278C\]                                                                                                      

  c.\[2696G \> C\];\               p.\[R899P\];\            Congenital                 Mild                 NA                    Dutch            \[[@B14-genes-10-00735]\]
  \[5934C \> T\]                   \[T1978G\]                                                                                                      

  c.\[2825_2827delAGA\];\          p.\[?\];\                Childhood                  Mild--Moderate       NA                    American         \[[@B19-genes-10-00735]\]
  \[4217C \> A\]                   \[A1406E\]                                                                                                      

  c.\[2863G \> T\];\               p.\[E955X\];\            NA                         NA                   NA                    Turkey           \[[@B18-genes-10-00735]\]
  \[2863G \> T\]                   \[E955X\]                                                                                                       

  c.\[3061C \> T\];\               p.\[R1021X\];\           1--10 y.o.                 Severe               Progressive           Netherlands      \[[@B14-genes-10-00735],[@B22-genes-10-00735]\]
  \[5885C \> T\]                   \[T1962M\]                                                                                                      

  c.\[3061 + 1G \> A\];\           p.\[?\];\                Congenital                 Moderate             NA                    Netherlands      \[[@B14-genes-10-00735],[@B22-genes-10-00735]\]
  \[6353G \> A\]                   \[G2118E\]                                                                                                      

  c.\[3071A \> G\];\               p.\[Y1024C\];\           Early-onset                Severe--profound     NA                    Italy            \[[@B28-genes-10-00735]\]
  \[3071A \> G\]                   \[Y1024C\]                                                                                                      

  c.\[3076G \> T\];\               p.\[V1026F\];\           3 y.o.                     Profound             Non-progressive       Japanese         \[[@B15-genes-10-00735]\]
  \[4375 + 1G \> T\]               \[?\]                                                                                                           

  c.\[3169C \> T\];\               p.\[V1026F\];\           Congenital                 Severe               Stable                Dutch            \[[@B14-genes-10-00735]\]
  \[6353G \> A\]                   \[G2118E\]                                                                                                      

  c.\[3371G \>A\];\                p.\[A1124H\];\           NA                         NA                   NA                    Cameroon         \[[@B29-genes-10-00735]\]
  \[3979T \> A\]                   \[P1327I\]                                                                                                      

  c.\[3571A \> G\];\               p.\[T1191A\];\           Congenital                 Severe-profound      NA                    Spanish          \[[@B30-genes-10-00735]\]
  \[3571A \> G\]                   \[T1191A\]                                                                                                      

  c.\[3748 + 1G \> C\];\           p\[?\];\                 Congenital                 Moderate--severe     Stable--Progressive   Dutch            \[[@B14-genes-10-00735]\]
  \[6353G \> A\]                   \[G2118E\]                                                                                                      

  c.\[4099G \> T\];\               p.\[E1367X\];\           Congenital                 Severe--profound     NA                    American         \[[@B19-genes-10-00735]\]
  \[6162_6164delCCT\]              \[F2055Nfs \* 157\]                                                                                             

  c.\[4212 + 1G \> A\];\           p.\[?\];\                Congenital--7 y.o.         Mild--Severe         Progressive           Japanese         \[[@B17-genes-10-00735]\]
  \[5674G \> T\]                   \[V1892F\]                                                                                                      

  c.\[4480C \> T\];\               p.R1494X\[R1494X\]       NA                         NA                   NA                    Turkey           \[[@B18-genes-10-00735]\]
  \[4480C \> T\]                                                                                                                                   

  c.\[4480C \> T; 4526G \> A\];\   p.\[R1494X;G1509E\];\    Congenital                 Mild--moderate       NA                    American         \[[@B19-genes-10-00735]\]
  \[4480C \> T; 4526G \> A\]       \[R1494X;G1509E\]                                                                                               

  c.\[4480C \> T\];\               p.\[R1494X\];\           40 y.o.                    Severe--profound     Progressive           American         \[[@B20-genes-10-00735]\]
  \[4526G \> A\]                   \[G1509E\]                                                                                                      

  c.\[4480C \> T\];\               p.\[R1494X\];\           NA                         Moderate--severe     Non-progressive       Japanese         \[[@B21-genes-10-00735]\]
  \[5869G \> T\]                   \[E1957X\]                                                                                                      

  c.\[4480C \> T; 4526G \> A\];\   p.\[R1494X; G1509E\];\   Childhood                  Severe-profound      NA                    American         \[[@B19-genes-10-00735]\]
  \[6598delG\]                     \[D2200Mfs \* 21\]                                                                                              

  c.\[4623C \>G\];\                p.\[Y1541X\];\           2 y.o.                     Severe               NA                    Czech            \[[@B31-genes-10-00735]\]
  \[5545G \> A\]                   \[G1849R\]                                                                                                      

  c.\[4714C \>T\];\                p.\[R1572X\];\           Prelingual                 Severe--profound     Non-progressive       Ashkenazi Jews   \[[@B32-genes-10-00735]\]
  \[4714C \> T\]                   \[R1572X\]                                                                                                      

  c.\[5894dupG\];\                 c.\[?\];\                Prelingual                 Profound             Na                    Arab             \[[@B33-genes-10-00735]\]
  \[5894dupG\]                     \[?\]                                                                                                           

  c.\[5948C \> T\];\               p.\[S1983F\];\           Congenital                 Severe--profound     Non-progressive       Chinese          \[[@B34-genes-10-00735]\]
  \[5948C \> T\]                   \[S1983F\]                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HL: hearing loss; NA: not available. ＊ Phasing of the three variants were unknown. \* This asterisk indicates the numbers of frameshifts.

genes-10-00735-t004_Table 4

###### 

Haplotype analysis of *LOXHD1* recurrent variation, c.4212 + 1G \> A.

  Distance from the c.4212 + 1G \> A Variation (bp)   Allele Frequency (HapMap-JPT)   Marker              No. 2   No. 3   No. 4   No. 5   No. 7   No. 25
  --------------------------------------------------- ------------------------------- ------------------- ------- ------- ------- ------- ------- --------
  980,731                                             C 0.30 T 0.70                   rs868409            C/T     C/T     C/C     C/T     C/T     C/C
  926,737                                             A 0.38 G 0.62                   rs4890557           A/G     A/G     G/G     A/G     A/A     G/G
  877,703                                             A 0.27 G 0.73                   rs17732049          A/G     G/G     G/G     G/G     A/G     G/G
  862,524                                             T 0.26 C 0.74                   rs3786397           C/C     T/C     C/C     T/C     C/C     C/C
  860,937                                             T 0.35 C 0.65                   rs1552329           T/C     C/C     C/C     T/C     C/C     C/C
  811,321                                             G 0.37 A 0.63                   rs3760578           G/G     A/A     A/A     A/A     A/A     A/A
  668,955                                             T 0.26 C 0.74                   rs12456289          C/C     C/C     C/C     C/C     C/C     C/C
  626,721                                             C 0.26 T 0.74                   rs8097963           T/T     T/T     T/T     T/T     T/T     T/T
  570,604                                             A 0.28 T 0.72                   rs8087546           T/T     T/T     T/T     T/T     T/T     T/T
  524,148                                             A 0.32 G 0.68                   rs673123            G/G     A/G     G/G     G/G     G/G     G/G
  332,094                                             C 0.47 T 0.53                   rs9956574           C/T     C/T     T/T     C/T     T/T     T/T
  233,342                                             C 0.38 T 0.62                   rs4890637           T/T     T/T     T/T     C/T     T/T     T/T
  134,221                                             T 0.32 C 0.68                   rs16978558          C/C     C/C     C/C     C/C     C/C     C/C
  122,941                                             C 0.27 A 0.73                   rs3911131           C/A     A/A     A/A     A/A     A/A     A/A
  24,152                                              G 0.27 T 0.73                   rs8084298           T/T     T/T     T/T     T/T     T/T     T/T
  15,561                                              A 0.29 G 0.71                   rs426303            G/G     G/G     G/G     G/G     G/G     G/G
  0                                                                                   c.4212 + 1 G \> A   \-      \-      \-      \-      \-      \-
  108,292                                             A 0.23 C 0.77                   rs16939868          C/C     C/C     C/C     C/C     C/C     C/C
  206,155                                             C 0.27 G 0.73                   rs4121822           C/C     C/C     C/G     C/G     C/G     C/C
  220,199                                             G 0.27 A 0.73                   rs4449041           A/A     A/A     G/G     A/A     G/G     A/A
  282,037                                             C 0.28 T 0.72                   rs513775            T/T     T/T     T/T     C/T     T/T     T/T
  290,228                                             A 0.32 T 0.68                   rs578451            T/T     T/T     A/T     A/T     T/T     T/T
  296,452                                             A 0.26 G 0.74                   rs2576050           G/G     G/G     G/G     A/G     G/G     G/G
  444,615                                             A 0.28 G 0.72                   rs2576040           G/G     G/G     G/G     A/G     G/G     G/G
  538,731                                             G 0.26 A 0.74                   rs16949034          A/A     A/A     G/A     A/A     G/A     A/A
  615,845                                             A 0.27 G 0.73                   rs1434529           G/G     G/G     G/G     G/G     G/G     G/G
  631,424                                             C 0.24 G 0.76                   rs1398218           G/G     G/G     G/G     G/G     G/G     G/G
  733,575                                             C 0.35 T 0.65                   rs1434506           C/T     C/C     C/T     C/T     T/T     C/C
  805,030                                             C 0.33 T 0.67                   rs1893784           C/T     T/T     C/T     T/T     C/T     T/T
  822,756                                             C 0.39 T 0.61                   rs4986222           C/C     C/C     C/T     C/T     C/T     C/C
  973,908                                             C 0.36 T 0.64                   rs1108062           T/T     T/T     T/T     T/T     C/T     T/T
  1,042,874                                           G 0.33 A 0.67                   rs3813071           A/A     A/A     G/A     A/A     A/A     A/A
  1,100,150                                           T 0.30 G 0.70                   rs12969708          G/G     G/G     T/G     G/G     G/G     G/G

Pink squares indicate heterozygotes and blues indicate homozygotes of minor allele.
